Thema: Presse: Orphan drug designation for panzem (2ME2) in glioblastoma
Presse: Orphan drug designation for panzem (2ME2) in glioblastoma
Max[a]
01.08.2006 20:56:30
EntreMed Granted Orphan Drug Designation for Panzem (2ME2) In Glioblastoma
EntreMed, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead drug candidate, 2-methoxyestradiol (2ME2 or Panzem®), for the treatment of glioblastoma multiforme (GBM), an often fatal form of brain cancer.
The FDA accepted EntreMed's application upon review of data from in vitro studies in glioma cell lines that demonstrate the antiproliferative activity of 2ME2. Additionally, results from in vivo studies in a preclinical model of glioblastoma demonstrate antitumor activity of 2ME2. In January 2006, EntreMed initiated a Phase 2 study in patients with glioblastoma multiforme at the Brain Tumor Center at Duke University Medical Center.
Carolyn F. Sidor, M.D., EntreMed Vice President and Chief Medical Officer commented on the designation, "Glioblastoma is the most common malignant primary brain tumor representing approximately 12 to 15% of all brain tumors. Based on results from both preclinical experiments and mechanism-of-action studies, we believe that 2ME2 may be particularly well-suited for this patient population because these tumors are highly angiogenic and frequently harbor PTEN mutations, which result in high levels of HIF-1alpha protein. We have now received orphan drug designation for 2ME2 (Panzem®) in three cancer indications."
About Glioblastoma
Approximately 40,000 cases of primary central nervous system (CNS) cancers are diagnosed each year in the United States, of which 17,000 are malignant tumors. Malignant CNS tumors cause approximately 13,000 deaths per year, or about three-fourths of the new annual malignant cases. Glioblastoma multiforme (GBM), also known as grade IV astrocytoma, is the most common and aggressive type of primary brain tumor. GBMs account for approximately 52% of all primary brain tumors. The tumor forms in the glial (supportive) tissue of the brain and invades adjacent tissue. The tumor cells do not spread throughout the body and symptoms are caused by the tumor invading the brain. These tumors have significant regions of hypoxia and are highly dependent on angiogenesis for growth.
(posted on 28/06/2006)
ROCKVILLE, Md., June 28 PRNewswire
EntreMed, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead drug candidate, 2-methoxyestradiol (2ME2 or Panzem®), for the treatment of glioblastoma multiforme (GBM), an often fatal form of brain cancer.
The FDA accepted EntreMed's application upon review of data from in vitro studies in glioma cell lines that demonstrate the antiproliferative activity of 2ME2. Additionally, results from in vivo studies in a preclinical model of glioblastoma demonstrate antitumor activity of 2ME2. In January 2006, EntreMed initiated a Phase 2 study in patients with glioblastoma multiforme at the Brain Tumor Center at Duke University Medical Center.
Carolyn F. Sidor, M.D., EntreMed Vice President and Chief Medical Officer commented on the designation, "Glioblastoma is the most common malignant primary brain tumor representing approximately 12 to 15% of all brain tumors. Based on results from both preclinical experiments and mechanism-of-action studies, we believe that 2ME2 may be particularly well-suited for this patient population because these tumors are highly angiogenic and frequently harbor PTEN mutations, which result in high levels of HIF-1alpha protein. We have now received orphan drug designation for 2ME2 (Panzem®) in three cancer indications."
About Glioblastoma
Approximately 40,000 cases of primary central nervous system (CNS) cancers are diagnosed each year in the United States, of which 17,000 are malignant tumors. Malignant CNS tumors cause approximately 13,000 deaths per year, or about three-fourths of the new annual malignant cases. Glioblastoma multiforme (GBM), also known as grade IV astrocytoma, is the most common and aggressive type of primary brain tumor. GBMs account for approximately 52% of all primary brain tumors. The tumor forms in the glial (supportive) tissue of the brain and invades adjacent tissue. The tumor cells do not spread throughout the body and symptoms are caused by the tumor invading the brain. These tumors have significant regions of hypoxia and are highly dependent on angiogenesis for growth.
(posted on 28/06/2006)
ROCKVILLE, Md., June 28 PRNewswire
Max[a]
